Activation of recombinases at specific DNA loci by zinc-finger domain insertions.

Autor: Mukhametzyanova L; Medical Systems Biology, Medical Faculty, Technical University Dresden, Dresden, Germany., Schmitt LT; Medical Systems Biology, Medical Faculty, Technical University Dresden, Dresden, Germany.; Seamless Therapeutics GmbH, Dresden, Germany., Torres-Rivera J; Medical Systems Biology, Medical Faculty, Technical University Dresden, Dresden, Germany., Rojo-Romanos T; Medical Systems Biology, Medical Faculty, Technical University Dresden, Dresden, Germany.; Seamless Therapeutics GmbH, Dresden, Germany., Lansing F; Medical Systems Biology, Medical Faculty, Technical University Dresden, Dresden, Germany.; Seamless Therapeutics GmbH, Dresden, Germany., Paszkowski-Rogacz M; Medical Systems Biology, Medical Faculty, Technical University Dresden, Dresden, Germany., Hollak H; Medical Systems Biology, Medical Faculty, Technical University Dresden, Dresden, Germany.; Seamless Therapeutics GmbH, Dresden, Germany., Brux M; Medical Systems Biology, Medical Faculty, Technical University Dresden, Dresden, Germany., Augsburg M; Medical Systems Biology, Medical Faculty, Technical University Dresden, Dresden, Germany., Schneider PM; Medical Systems Biology, Medical Faculty, Technical University Dresden, Dresden, Germany.; Seamless Therapeutics GmbH, Dresden, Germany., Buchholz F; Medical Systems Biology, Medical Faculty, Technical University Dresden, Dresden, Germany. frank.buchholz@tu-dresden.de.
Jazyk: angličtina
Zdroj: Nature biotechnology [Nat Biotechnol] 2024 Dec; Vol. 42 (12), pp. 1844-1854. Date of Electronic Publication: 2024 Jan 31.
DOI: 10.1038/s41587-023-02121-y
Abstrakt: Recombinases have several potential advantages as genome editing tools compared to nucleases and other editing enzymes, but the process of engineering them to efficiently recombine predetermined DNA targets demands considerable investment of time and labor. Here we sought to harness zinc-finger DNA-binding domains (ZFDs) to program recombinase binding by developing fusions, in which ZFDs are inserted into recombinase coding sequences. By screening libraries of hybrid proteins, we optimized the insertion site, linker length, spacing and ZFD orientation and generated Cre-type recombinases that remain dormant unless the insertionally fused ZFD binds its target site placed in the vicinity of the recombinase binding site. The developed fusion improved targeted editing efficiencies of recombinases by four-fold and abolished measurable off-target activity in mammalian cells. The ZFD-dependent activity is transferable to a recombinase with relaxed specificity, providing the means for developing fully programmable recombinases. Our engineered recombinases provide improved genome editing tools with increased precision and efficiency.
Competing Interests: Competing interests: L.M., J.T.-R. and F.B. have filed a patent application based on work presented in this paper. T.R.-R., F.L., M.P.-R. and F.B. are co-founders and shareholders of Seamless Therapeutics GmbH. The other authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: